Journal: Molecular Therapy. Nucleic Acids

Article Title: Downregulation of hepatic lipopolysaccharide binding protein improves lipogenesis-induced liver lipid accumulation

doi: 10.1016/j.omtn.2022.08.003

Figure Lengend Snippet: In vitro validation of Lbp siRNAs and in vivo effect of Lbp UNA-siRNA delivered through lipid nanoparticles (A) Effect of several doses of chemically unmodified and modified (UNA) siRNA (si69107, si69108, si69109) against Lbp mRNA sequence in Hepa1-6 cell line. (B) Effect of chemically unmodified (1 and 3 mg/kg) and chemically modified (UNA, 1 and 3 mg/kg) LNP- Lbp siRNA on plasma LBP at days 3, 6, 10, and 12 after injection. (C) Effect of chemically modified (UNA, 1 and 3 mg/kg) LNP- Lbp siRNA on liver Lbp gene expression 3 days after second injection. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared with 0 pmol/L or vehicle. (D) Effects of 6-month LNP- Lbp UNA-siRNA administration in HFHS-fed mice on liver, inguinal WAT (iWAT), and perigonadal WAT (pgWAT) Lbp mRNA levels and plasma Lbp concentration in male and female mice. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared with CD; † p < 0.05, †† p < 0.01, and ††† p < 0.001 compared with HFHS.

Article Snippet: Plasma LBP (HK205-02, LBP mouse ELISA kit, Hycult Biotech, Plymouth Meeting, PA, USA), insulin (90080, Crystal Chem, Zaandam, the Netherlands), glucose (Accutrend; Roche Diagnostics, Mannheim, Germany), and ALT activity (Alfa Wasserman/Vet Axcel Reagent SA1046) were measured using commercial kits according to manufacturer’s instructions.

Techniques: In Vitro, In Vivo, Modification, Sequencing, Injection, Expressing, Concentration Assay

Journal: Molecular Therapy. Nucleic Acids

Article Title: Downregulation of hepatic lipopolysaccharide binding protein improves lipogenesis-induced liver lipid accumulation

doi: 10.1016/j.omtn.2022.08.003

Figure Lengend Snippet: Association of liver LBP with expression of de novo lipogenesis genes in morbidly obese human subjects (A and B) Plasma LBP concentration (A) and liver, SAT, and VAT LBP mRNA levels (B) according to NAFLD. (C) Bivariate correlations between liver LBP mRNA levels and plasma LBP concentration in morbidly obese participants. (D–F) Bivariate correlations between liver LBP and SREBF1 (D), FASN (E), and ACACA (F) mRNA levels. (G) Bivariate correlations between plasma LBP concentration and liver FASN mRNA levels.

Article Snippet: Plasma LBP (HK205-02, LBP mouse ELISA kit, Hycult Biotech, Plymouth Meeting, PA, USA), insulin (90080, Crystal Chem, Zaandam, the Netherlands), glucose (Accutrend; Roche Diagnostics, Mannheim, Germany), and ALT activity (Alfa Wasserman/Vet Axcel Reagent SA1046) were measured using commercial kits according to manufacturer’s instructions.

Techniques: Expressing, Concentration Assay

Journal: Temperature: Multidisciplinary Biomedical Journal

Article Title: Effects of dairy products on intestinal integrity in heat-stressed pigs

doi: 10.4161/temp.29561

Figure Lengend Snippet: Figure 2. Effects of feeding diets containing no test product (Ct), or 80% milk whey protein (WP) + 20% colostral whey protein (CWP; WP80), 98% WP + 2% CWP (WP98), 100% WP (WP100) test products on plasma ( A ) L-lactate, ( B ) D-lactate, and ( C ) lipopolysaccharide binding protein (LBP) concentrations of pigs during period 1 (P1; thermoneutral conditions: 19 °C; ~46% humidity) and at the end of period 2 (P2; heat stress conditions for 24 h: 32 °C; ~26% humidity). *Represents differences between treatments during period 2 with period 1 as a covariate.

Article Snippet: Plasma LBP concentrations were determined using an ELISA kit (Hycult® biotech, cat# HK503).

Techniques: Binding Assay

Journal: Antioxidants

Article Title: The Effects of Beverage Intake after Exhaustive Exercise on Organ Damage, Inflammation and Oxidative Stress in Healthy Males

doi: 10.3390/antiox10060866

Figure Lengend Snippet: Changes in plasma and urinary ( A ) L-FABP, ( B ) NGAL, ( C ) KIM-1, ( D ) RBP-4, ( E ) I-FABP, ( F ) I-BABP, ( G ) LBP and ( H ) myoglobin. Values are presented as mean ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. Pre. † p < 0.05 REH vs. CON in each time point. L-FABP, liver-fatty acid binding protein; NGAL, neutrophil gelatinase-associated lipocalin; KIM-1, kidney injury molecule 1; RBP-4, retinol binding protein 4; I-FABP, intestine-fatty acid binding protein; I-BABP, ileal-bile acid binding protein; LBP, lipopolysaccharide binding protein; REH, rehydrate trial; CON, control trial.

Article Snippet: Plasma and urinary myeloperoxidase (MPO) and calprotectin concentrations and plasma lipopolysaccharide binding protein (LBP) concentrations were measured using ELISA kits from Hycult Biotech (Uden, The Netherlands).

Techniques: Binding Assay